Logo

Verona Pharma Reports Completion of Enrollment for Ensifentrine in P-III (ENHANCE-2) Trial to Treat COPD

Share this
Verona Pharma Reports Completion of Enrollment for Ensifentrine in P-III (ENHANCE-2) Trial to Treat COPD

Verona Pharma Reports Completion of Enrollment for Ensifentrine in P-III (ENHANCE-2) Trial to Treat COPD

Shots:

  • The P-III (ENHANCE-2) trial evaluates the efficacy & safety of ensifentrine (3mg) as monothx. & added on to LAMA or LABA vs PBO in 800 patients with COPD across US & EU for 24wks. The results are expected in Q3’22 while (ENHANCE-1) trial result at the end of 2022
  • The 1EPs include an improvement in lung function over 12hrs. after 12wks. The 2EPs include COPD symptoms & health-related QoL @24wks. via validated PROs tools, SGRQ & E-RS while an additional lung function EPs including peak & morning trough FEV1 will also be evaluated
  • The company is planning to file an NDA with the US FDA in H1’23. In prior clinical studies, the therapy showed improvements in lung function, symptoms & QoL

Ref: Globe Newswire | Image: Share Talk

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions